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The c-Jun N-terminal kinase (JNK) pathway is a dual-functional oncogenic signaling that exerts both anti-
and pro-tumor activities. However, the mechanism by which JNK switches its oncogenic roles depending
on different cellular contexts has been elusive. Here, using the Drosophila genetics, we show that
hyperactive Ras acts as a signaling switch that converts JNK's role from anti- to pro-tumor signaling
through the regulation of Hippo signaling activity. In the normal epithelium, JNK signaling antagonizes
the Hippo pathway effector Yorkie (Yki) through elevation of Warts activity, thereby suppressing tissue
growth. In contrast, in the presence of hyperactive Ras, JNK signaling enhances Yki activation by accu-
mulating F-actin through the activity of the LIM domain protein Ajuba, thereby promoting tissue growth.
We also ﬁnd that the epidermal growth factor receptor (EGFR) signaling uses this Ras-mediated con-
version of JNK signaling to promote tissue growth. Our observations suggest that Ras-mediated switch of
the JNK pathway from anti- to pro-tumor signaling could play crucial roles in tumorigenesis as well as in
normal development.
& 2015 Elsevier Inc. All rights reserved.Introduction
Cancer development is driven by deregulation of cellular sig-
naling that leads to stimulated cell proliferation and reduced cell
death (Christofori, 2006; Hanahan and Weinberg, 2011). The c-Jun
N-terminal kinase (JNK) pathway, an evolutionally conserved
mitogen-activated protein kinase cascade, is one of the crucial
oncogenic signaling that regulates cell proliferation and cell death
(Karin and Gallagher, 2005; Rincón and Davis, 2009; Weston and
Davis, 2007). Intriguingly, the JNK pathway has long been impli-
cated in cancer development as both pro-cancer and anti-cancer
signaling (Bode and Dong, 2007; Bubici and Papa, 2014; Gonzalez,
2013; Karin and Gallagher, 2005). For instance, deletion of JNK1
gene suppresses tumor growth in mouse models of liver (Hui et al.,
2008) or lung (Cellurale et al., 2011) cancer, and decreases sus-
ceptibility to diethylnitrosamine-induced hepatocellular carci-
noma (HCC) formation (Sakurai et al., 2006). However, in other
mouse models of cancer, deletion of JNK1 or JNK2 genes enhances
prostate cancer development (Hübner et al., 2012) or papilloma
formation in the skin (She et al., 2002), and increases the fre-
quency of breast cancer development (Cellurale et al., 2010).raduate School of Biostudies,
Kyoto 606-8501, Japan.Indeed, somatic mutations for jnk genes or the MKK4 (a JNK
kinase) gene have been identiﬁed in many types of human cancers
such as glioma, colorectal, ovarian, and head and neck cancers
(Greenman et al., 2007; Whitmarsh and Davis, 2007). Thus, JNK
signaling could play critical roles in cancer regulation as both pro-
and anti-tumor growth signaling. However, the mechanism by
which JNK switches its pro- and anti-tumor activities in different
cellular contexts has been elusive.
Drosophila provides a powerful genetic model for studying in vivo
roles and the mechanisms of cellular signaling during tumor growth
and progression (Gonzalez, 2013; Miles et al., 2011; Ohsawa et al.,
2014; Vidal and Cagan, 2006). In Drosophila, JNK is encoded by a
single gene basket (bsk). Interestingly, the Drosophila JNK pathway
has also been shown to act as both pro- and anti-tumor signaling in
imaginal epithelia (Enomoto and Igaki, 2011; Igaki and Miura, 2014;
Pastor-Pareja and Xu, 2013; Patel and Edgar, 2014; Vidal, 2010). For
instance, JNK signaling promotes Ras-induced tumor growth and
progression in imaginal tissue (Brumby et al., 2011; Chi et al., 2010;
Igaki et al., 2006; Uhlirova and Bohmann, 2006). In addition, ima-
ginal disc entirely mutant for the effectors for endocytosis and
the endosomal sorting complex required for transport (ESCRT)
family develop neoplastic tumors through activation of JNK signaling
and JAK-STAT signaling (Thomas and Strutt, 2014; Woodﬁeld et al.,
2013). Tissues with Src64B-activating cells at the large compartment
are developed into tumors through JNK signaling (Fernandez et al.,
2014). Furthermore, in the ﬂy model of type 2 diabetes, JNK
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clones of Ras-activated cells mutant for C-terminal Src kinase (csk)
(Hirabayashi et al., 2013). In contrast, the JNK pathway has been
shown to act as a tumor suppressor in clones of cells with some
oncogenic mutations. For instance, JNK signaling blocks tumor
growth of oncogenic clones mutant for neoplastic tumor suppressors
such as scribble (scrib, an apico-basal polarity gene) (Brumby and
Richardson, 2003; Chen et al., 2012; Igaki et al., 2009; Leong et al.,
2009), rab5 (a component of the early endosome) (Takino et al.,
2014) and vps25 (a component of the ESCRT complex) (Herz et al.,
2006). Furthermore, JNK signaling suppresses tumor growth of Src-
activating cells surrounded by wild-type tissue (Enomoto and Igaki,
2013). These observations in Drosophila have revealed evolutionary
conservation of the dual functions of JNK signaling in tumor growth
regulation, which indicates the signiﬁcance of using the Drosophila
model to understand the basic principle of this phenomenon. Here,
using the Drosophila imaginal disc as a model system, we investigate
the mechanism by which JNK switches its pro- and anti-tumor sig-
naling in different oncogenic contexts. We show that JNK suppresses
tumor growth through activation of the Hippo pathway in cells with
normal Ras activity, while JNK promotes tumor growth by inacti-
vating the Hippo pathway through F-actin accumulation in cells
aberrantly activating Ras signaling.Materials and methods
Fly strains and generation of clones
Fluorescently labeled mitotic clones were produced in larval ima-
ginal discs using the following strains: eyFLP1; Act4yþ4Gal4, UAS-
GFP; FRT82B, Tub-Gal80 (82B-tester), Tub-Gal80, FRT40A; eyFLP6,
Act4yþ4Gal4, UAS-GFP (40A-tester), and FRT42D, Tub-Gal80;
eyFLP6, Act4yþ4Gal4, UAS-GFP (42D-tester). Additional strains used
are the following: hpo42-47 (D.J. Pan), scrib1 (D. Bilder), wtsX1, UAS-Wts
(T. Xu), UAS-BskDN (T. Adachi-Yamada), UAS-CD8-PARP-venus (Y. Hir-
omi), UAS-EigerW, UAS-Eigerregg1 (M. Miura), UAS-Eiger (K. Basler),
dia5, ex697 (ex-lacZ), fjp1 (fj-lacZ), ftk07918, msn06946 (msn-lacZ), thj5C8
(diap1-lacZ), nubbin-Gal4, UAS-DiaCA, UAS-dJub-RNAi, UAS-EGFRCA
(UAS-EGFRiso2A887T), UAS-HepAct, UAS-Rac1DN (UAS-Rac1N17), UAS-
RasV12, UAS-Src64B, UAS-Ykiwt, UAS-YkiS168A, UASYkiS111AS168AS250A,
(Bloomington Stock Center), UAS-wts-RNAi12072R-1, UAS-yki-RNAi4005R-2
(National Institute of Genetics Stock Center).
Histology
Larval tissues were stained with standard immunochemical
procedures using mouse anti-β-galactosidase antibody (Sigma;
1:250), rabbit anti-human cleaved PARP antibody (Cell signaling;
1:200), guinea pig anti-Cyclin E antibody (T. Orr-Weaver), mouse
anti-Cyclin E antibody (H. Richardson), chick anti-GFP antibody
(Aves Labs; 1:200), Alexa546- or Alexa647-conjugated phalloidin
(Molecular Probes; 1:50), and mounted with DAPI-containing
Slow Fade Gold Antifade Reagent (Molecular Probes). Images were
taken with a Zeiss LSM510 META and a Leica TCS-SP5 confocal
microscopes.
Detection of phosphorylated Yki
Adult heads from ﬂies expressing Yki-V5, Yki-V5þEiger, or Yki-
V5þHpoþWts were lysed in IP buffer [50 mM Tris–HCl (pH 7.5),
0.1 M NaCl, 1 mM DTT, 1 mM PMSF, 1% NP-40, protease inhibitor
cocktail (Nakarai Tech., Kyoto)]. Yki-V5 was immunoprecipitated
from the lysate with mouse anti-V5 antibody (MBL; 1:100) and
subjected to SDS-PAGE. Total Yki protein or phosphorylated Yki
(Ser168) was detected using mouse anti-V5 antibody (MBL; 1:1000)or rabbit anti-phosphoSer168 Yki antibody (D.J. Pan; 1:1000). The
relative ratio of phosphorylated Yki and total Yki proteins were
quantiﬁed by Image J software (National Institute of Health).Results
JNK signaling acts as an anti-tumor pathway in Hippo pathway
mutant clones
In Drosophila imaginal epithelium, clones of oncogenic cells
mutant for scrib or overexpressing Src64B are eliminated by JNK-
dependent cell death (Brumby and Richardson, 2003; Enomoto and
Igaki, 2013; Igaki et al., 2009) (Fig. S1A–D, data not shown), showing
an anti-tumor activity of JNK signaling in these mutant cells. Inter-
estingly, when JNK signaling is blocked, these mutant clones over-
grow with highly elevated activity of the Hippo pathway effector
Yorkie (Yki) (Chen et al., 2012; Doggett et al., 2011; Enomoto and
Igaki, 2013) (Fig. S1C and D, compare to Fig. S1A and B). In addition,
overgrowth of these oncogenic clones, which is induced by JNK
inhibition, is blocked by reduction in Yki activity (Chen et al., 2012;
Enomoto and Igaki, 2013) (Fig. S1E and F). These observations sug-
gest that the JNK pathway acts as an anti-tumor signaling in onco-
genic scrib or Src-activating clones through inhibition of Yki activity.
We therefore investigated the molecular link between JNK
signaling and Yki inhibition. Yki is a transcriptional coactivator
that promotes tissue growth by stimulating cell proliferation and
cell survival and is negatively regulated by the Hippo pathway
components such as Fat (Ft), Salvador (Sav), Hippo (Hpo), Mats and
Warts (Wts) (Halder and Johnson, 2011; Irvine, 2012; Pan, 2010;
Zhao et al., 2010). We ﬁrst examined whether JNK signaling can
block tissue overgrowth caused by mutations in these different
Hippo pathway components. In eye imaginal disc, activation of JNK
signaling by overexpression of Eiger (a Drosophila ortholog of TNF
that acts as a physiological ligand for JNK signaling) leads to
moderate tissue growth inhibition (Ohsawa et al., 2012) (Fig. 1A
and B). Signiﬁcantly, JNK activation by Eiger strongly suppressed
tissue overgrowth caused by mutations in the Hippo pathway
components such as ft and hpo (Fig. 1A–F). In addition, Yki acti-
vation, which was visualized by its transcriptional targets fj-lacZ
and ex-lacZ, in ft or hpo clones was strongly blocked by JNK acti-
vation (Fig. 1G–J). These results suggest that JNK signaling nega-
tively regulates Yki activity by modulating the Hippo pathway at
the downstream of Fat and Hpo.
JNK signaling does not exert its anti-tumor activity in wts mutant
clones
We therefore sought to identify the Hippo pathway component
(s) that is directly affected by JNK signaling. Strikingly, we found
that JNK activation had no effect on tissue overgrowth caused by
mutations or RNAi of wts ( Figs. 2A, B and S2A, B), a kinase that
phosphorylates and inhibits Yki (Dong et al., 2007). In addition,
JNK activation did not block Yki activation in wts clones (Fig. 2C
and D). These results indicate that JNK activation does not affect
Yki activity in the absence of Wts. To further conﬁrm this, we
examined clones of cells overexpressing Src, which leads to JNK
activation that antagonizes Yki activity (Fig. S1B, D and F) (Eno-
moto and Igaki, 2013). Consistent with the data using Eiger,
overexpression of Src64B, which also causes JNK activation,
strongly suppressed growth of these hpo or savmutant clones (Fig.
S2C, and data not shown). In contrast, overexpression of Src64B in
wts mutant clones did not suppress their growth; instead, Src64B
overexpression strongly enhanced growth of wts clones and led to
tumorous overgrowth (Fig. S2D, compare to Fig. 2A). Thus, in the
absence of Wts, JNK signaling fails to exert its anti-tumor activity.
Fig. 1. JNK signaling antagonizes tissue overgrowth caused by mutations in the Hippo pathway components.
(A–F) Eye-antennal discs or eyes of adult ﬂies bearing GFP-labeled wild-type clones (A), Eiger-expressing clones (B), ft mutant clones (C), ft mutant clones expressing Eiger
(D), hpomutant clones (E), and hpomutant clones expressing Eiger (F) are shown. (G–J) ftmutant clones (G), ftmutant clones expressing Eiger (H), hpomutant clones (I), and
hpo mutant clones expressing Eiger (J) were induced in fj-lacZ/þ (G and H) or ex-lacZ/þ (I and J) eye-antennal discs. The reporter activity was visualized by anti-β-
galactosidase staining. Cell nuclei were stained with DAPI (blue). Clones were visualized by GFP ﬂuorescence in the adult (A″–F″). The arrow indicates endogenous fj-lacZ
activity (H′). See Supplementary Data for genotypes.
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through Wts.
To further conﬁrm the Wts-dependent inhibition of Yki activity
by JNK signaling, we examined the effect of JNK activation on Yki-
induced tissue overgrowth in the presence of Wts. Overexpression
of wild-type Yki (Ykiwt), which can be phosphorylated and inac-
tivated by Wts, in the wing pouch caused tumorous overgrowth
(Fig. 3C, compare to Fig. 3A). Simultaneous activation of JNK sig-
naling by overexpression of Eiger signiﬁcantly blocked
Ykiwt-induced tissue overgrowth (Fig. 3D), while JNK activation
alone showed a moderate effect on tissue growth (Fig. 3B).
Importantly, cell death was not markedly increased when JNK
signaling was co-activated (Fig. 3D′, compare to Fig. 3C′), as eval-
uated by the PARP-Venus caspase-activity probe. We also found
that JNK activation can suppress overgrowth of hpo mutant clones
even when cell death was blocked by overexpression of p35 (data
not shown), indicating that JNK signaling can attenuate tissue
growth without increasing cell death. We further examined the
JNK-induced inhibition of Yki activity in the adult eye using a weak
allele of UAS-Eiger (EigerW), which causes little effect on the eye
morphology when driven by GMR-Gal4 (Fig. 3F, compare to
Fig. 3E). Consistent with the data obtained in the wing disc, Yki-
induced overgrowth of the eye was signiﬁcantly suppressed by
EigerW-induced JNK activation (Fig. 3H, compare to Fig. 3G). Thus,
in the presence of Wts, JNK signaling can block Yki-induced tissue
overgrowth.JNK inhibits Yki activity through Wts
We next investigated the role of Wts in JNK-induced inhibition of
Yki activity using mutant Yki proteins that cannot be phosphorylated
by Wts. It has been reported that Wts inhibits Yki activity through
phosphorylation of Yki protein at three sites, Ser111, Ser168, and
Ser250 (Dong et al., 2007; Oh and Irvine, 2008; Oh and Irvine, 2009;
Ren et al., 2010). We ﬁrst examined whether JNK signaling can block
tissue overgrowth caused by overexpression of a mutant Yki with a
non-phosphorylatable mutation at Ser168 (YkiS168A), the phosphor-
ylation site required for Yki's cytoplasmic retention through binding
to 14-3-3 protein (Dong et al., 2007; Oh and Irvine, 2008). Over-
expression of YkiS168A in the posterior region of the eye disc resulted
in massive overgrowth of adult eye (Dong et al., 2007; Oh and Irvine,
2008, 2009; Ren et al., 2010) (Fig. S3C). We found that JNK activation
only slightly suppressed the YkiS168A-induced tissue overgrowth (Fig.
S3D, compared to Fig. S3C), as compared to the signiﬁcant suppres-
sion of Ykiwt-induced tissue overgrowth by JNK signaling (Fig. S3B,
compared to Fig. S3A). The slight suppression of YkiS168A-induced
tissue overgrowth by JNK could be due to other two phosphorylation
sites, Ser111 and Ser250, remain to be phosphorylated by Wts.
Consistent with the results in the eye disc, JNK activation slightly
suppressed tissue overgrowth caused by YkiS168A in the wing pouch
(Fig. 4C, compare to Fig. 4A). We therefore further examined the role
of Wts in JNK-induced inhibition of Yki using YkiS111AS168AS250A, all
three major phosphorylation sites of which are replaced with Ala-
nines. We found that JNK activation had little effect on tissue over-
growth caused by YkiS111AS168AS250A (Fig. 4D, compare to Fig. 4B).
Fig. 2. JNK signaling does not suppress tissue overgrowth caused by wts mutation.
(A–D) GFP-labeled wtsmutant clones (A and C) or wtsmutant clones expressing Eiger (B and D) were induced in þ/þ (A and B) or ex-lacZ/þ (C and D) eye-antennal disc. The
reporter activity was visualized by anti-β-galactosidase staining. Cell nuclei were stained with DAPI (blue).
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JNK kinase Hep (HepAct) was coexpressed (Fig. S3E and F), further
supporting the notion that Wts activity is required for JNK-induced
inhibition of Yki.
The fact that Wts activity is required for JNK-induced Yki inhi-
bition raised the possibility that JNK signaling leads to activation of
Wts and thereby attenuates Yki activity. To test this possibility, we
ﬁrst used a model of JNK-induced small eye phenotype, which could
involve JNK-dependent Yki inhibition. High level expression of Eiger
(Eigerregg1) in the eye disc by the GMR-Gal4 driver leads to a small
eye phenotype in the adult (Igaki et al., 2002; Moreno et al., 2002)
(Fig. 4E, compare to Fig. 3E, quantiﬁed in Fig. 4I). Importantly, the
small eye phenotype caused by GMR4Eiger is only partially sup-
pressed by coexpression of a caspase inhibitor p35 (Igaki et al., 2002;
Kanda et al., 2011; Moreno et al., 2002) (Fig. 4F, compare to Fig. 4E,
quantiﬁed in Fig. 4I), suggesting that the phenotype is caused not
only by increased cell death but also by decreased tissue growth
through inhibition of Yki. We found that reduction in wts expression
signiﬁcantly suppressed small eye phenotype caused by the eye disc
expressing both Eigerregg1 and p35 (Fig. 4G, compare to Fig. 4F,
quantiﬁed in Fig. 4I), suggesting that JNK signaling blocks tissue
growth through activation of Wts. Interestingly, reduction in hpo (an
upstream kinase of wts), using a null allele of the hpo gene, hpo42-47
(Wu et al., 2003), did not suppress small eye phenotype caused by
expression of Eigerregg1 and p35 (Fig. 4H, compare to Fig. 4G, quan-
tiﬁed in Fig. 4I), supporting the notion that JNK inhibits Yki through
activation of Wts. To directly test the possibility that JNK signaling
elevates Wts activity, we examined Wts-mediated phosphorylation
of Yki at Ser168 in the proteins extracted from the adult eyes
expressing V5-tagged Ykiwt with or without Eiger. Signiﬁcantly,
Ser168 phosphorylation of Yki was markedly increased by activation
of JNK signaling to a similar extent with activation of upstreamkinases Hpo and Wts (Fig. 4J, quantiﬁed in Fig. 4K). Together, these
data suggest that JNK signaling exerts its anti-tumor activity by
inhibiting Yki through activation of Wts.
Hyperactive Ras switches JNK's role from anti- to pro-tumor signaling
through F-actin-mediated regulation of the Hippo pathway
A series of genetic and biochemical data so far presented
indicate that JNK signaling inhibits tissue growth by countering
Yki activity. Intriguingly, however, it has been shown that in cer-
tain conditions JNK signaling promotes tissue growth by activation
of Yki (Doggett et al., 2011; Grusche et al., 2011; Menéndez et al.,
2010; Ohsawa et al., 2012; Robinson and Moberg, 2011; Sun and
Irvine, 2011). These facts suggest that there exists molecules/sig-
naling that switch JNK's activity from anti- to pro-Yki signaling. A
good candidate for such factor is hyperactive Ras signaling, as it
greatly enhances tumor growth in the presence of JNK activation
(Brumby et al., 2011; Chi et al., 2010; Hirabayashi et al., 2013; Igaki
et al., 2006; Uhlirova and Bohmann, 2006). Consistently, we have
previously found that co-activation of Ras and JNK signaling in the
imaginal tissue leads to inactivation of the Hippo pathway
(Ohsawa et al., 2012), and indeed found that blocking JNK activity
in clones expressing Eiger and RasV12 strongly suppressed Yki
activation (Fig. S4B, compare to Fig. S4A). We further observed that
overexpression of p35 in clones expressing Eiger did not increase
Yki activity (data not shown), suggesting that hyperactivation of
Ras signaling, but not simply its anti-apoptotic activity, is required
for Yki activation. We thus sought to identify the mechanism
underlying this Hippo pathway inactivation and found that over-
grown tissue activating both Ras and JNK signaling highly accu-
mulated F-actin (Fig. 5A), which has been shown to inactivate the
Hippo pathway (Fernández et al., 2011; Sansores-Garcia et al.,
Fig. 3. JNK signaling suppresses Yki-induced tissue overgrowth.
(A–D) Wild-type cells (A), Eiger-expressing cells (B), Ykiwt-expressing cells (C), or YkiwtþEiger-expressing cells (D) that are also expressing CD8-PARP-Venus were induced in
the wing pouch of the wing disc using the nubbin-Gal4 driver. Cell death was assessed by caspase activity that is visualized by anti-cleaved PARP staining (white). Cell nuclei
were stained with DAPI (blue). Scale bar, 100 μm. (E–H) Eyes of adult ﬂies expressing Gal4 alone (E), EigerW (F), Ykiwt (G), or YkiwtþEigerW (H) by the GMR-Gal4 driver are
shown. See Supplementary Data for genotypes.
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slightly detected in clones of cells solely activating JNK or Ras
signaling, respectively (Fig. S4C and D). These data suggest that
activation of Ras and JNK signaling inactivates the Hippo pathway
through F-actin accumulation. Indeed, blocking F-actin accumu-
lation by inhibiting a Rho GTPase Rac1 or its effector Diaphanous
(Dia) abolished Yki activation, as assessed by Yki target Cyclin E
(CycE) expression, as well as tissue overgrowth of clones activating
Ras and JNK signaling (Figs. 5B–D and S4E). It has been shown in
mammalian cells that a LIM domain protein Ajuba is required for
Rac activation and F-actin accumulation (Nola et al., 2011; Pratt
et al., 2005). Furthermore, the Drosophila ortholog of Ajuba, dJub,
has been shown to bind to Wts and negatively regulate the Hippo
pathway (Das Thakur et al., 2010; Reddy and Irvine, 2013; Sun and
Irvine, 2013). These observations suggest that dJub contributes to
inactivation of the Hippo pathway by regulating F-actin accumu-
lation. Interestingly, we found that a reduction in dJub expression
by djub-RNAi in clones of cells activating Ras and JNK signalingsigniﬁcantly blocked F-actin accumulation and Yki activation
(Fig. 5E and F). F-actin accumulation and Yki activation can also be
observed when a constitutively active form of Dia (DiaCA) is
overexpressed in the large area of the wing disc (Sansores-Garcia
et al., 2011) (Fig. S3D). Importantly, djub-RNAi did not affect
F-actin accumulation and Yki activation caused by DiaCA (Fig. S4G,
compare to Fig. S4F), indicating that dJub acts upstream of F-actin
accumulation. These data indicate that activation of Ras and JNK
signaling causes F-actin accumulation through dJub, Rac1, and Dia,
thereby leading to Yki activation.
It has recently been shown in Drosophila imaginal disc that
ectopic activation of epidermal growth factor receptor (EGFR)
signaling leads to inactivation of the Hippo pathway and sub-
sequent Yki activation via Ras signaling (Reddy and Irvine, 2013)
(Fig. S4H). On the other hand, hyperactivation of Ras signaling by
overexpression of oncogenic RasV12 only slightly activates Yki
(Enomoto and Igaki, 2013; Ohsawa et al., 2012). These ﬁndings
raised the possibility that activation of EGFR signaling causes
Fig. 4. JNK inhibits Yki activity through Wts.
(A–D) YkiS168A-expressing cells (A), YkiS111AS168AS250A-expressing cells (B), YkiS168AþEiger-expressing cells (C) or YkiS111AS168AS250AþEiger-expressing cells (D) that are also
expressing CD8-PARP-Venus were induced in the wing pouch of the wing disc using the nubbin-Gal4 driver. Cell death was visualized by anti-cleaved PARP staining (A′–D′;
white). Cell nuclei were stained with DAPI (A″–D″; blue). (E–H) Eyes of adult ﬂies expressing Eigerregg1 (E), Eigerregg1þp35 (F), Eigerregg1þp35 in wts/þ background (G), or
Eigerregg1þp35 in hpo/þ background (H) by the GMR-Gal4 driver are shown. (I) Quantiﬁcation of the size of adult eyes with indicated genotypes: (from left to right) GMR-
Gal4 (corresponding to Fig. 3E), GMR4Eigerregg1 (corresponding to Fig. 4E), GMR4Eigerregg1þp35 (corresponding to Fig. 4F), GMR4Eigerregg1þp35 in wts/þ background
(corresponding to Fig. 4G), and GMR4Eigerregg1þp35 in hpo/þ background (corresponding to Fig. 4H). (J) Immunoblot analysis for Yki phosphorylation at S168 (a Wts
phosphorylation site) using adult heads expressing Ykiwt, YkiwtþEiger, or YkiwtþHpoþWts. (K) A graph indicates the relative ratio of phosphorylated Yki proteins/total Yki
proteins. See Supplementary Data for genotypes.
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Fig. 5. Hyperactive Ras switches JNK's role from anti- to pro-tumor signaling through F-actin-mediated regulation of the Hippo pathway.
(A–J) Eye-antennal discs bearing GFP-labeled EigerþRasV12-expressing clones (A and B), EigerþRasV12þRac1DN-expressing clones (C and D), EigerþRasV12þdJub-RNAi-
expressing clones (E and F), EGFRCA-expressing clones in msn-lacZ/þ (G) or þ/þ (H) background, EGFRCAþBskDN-expressing clones (I), or hpo / clones expressing
EigerþRasV12 (J) are shown. F-actin (A, C, E, H, I and J), Yki activity (B, D, and F), or JNK activity (G) was visualized by phalloidin staining (A, C, E, H, I and J), anti-Cyclin E
staining (B, D, and F), or anti-β-galactosidase staining (G). Cell nuclei were stained with DAPI (blue). See Supplementary Data for genotypes. (K) A model for a hyperactive
Ras-mediated switch of the JNK's role from “anti-tumor” to “pro-tumor” signaling. See text for details.
M. Enomoto et al. / Developmental Biology 403 (2015) 162–171168activation of both Ras and JNK signaling, which cooperate to
inactivate the Hippo pathway through F-actin accumulation.
Indeed, we found that overexpression of a constitutively active
form of EGFR (EGFRCA) caused JNK activation (as visualized by
expression of JNK targetmisshapen (Mattila et al., 2005)) as well asaccumulation of F-actin (Fig. 5G and H). Furthermore, blocking JNK
signaling in clones of cells overexpressing EGFRCA suppressed
F-actin accumulation as well as tumorous overgrowth (Fig. 5I).
These data indicate that EGFR signaling-induced tumor growth
also involves cooperation between hyperactive Ras and JNK
M. Enomoto et al. / Developmental Biology 403 (2015) 162–171 169signaling that causes Yki activation through F-actin accumulation
(Fig. 5K).
Our observations described so far indicate that JNK exerts both
pro- and anti-tumor activity by hyperactive Ras-mediated switch of
Warts activity. To further conﬁrm this notion, we analyzed clones of
cells mutant for hpo simultaneously overexpressing Eiger
(hpo /þEiger) (Fig. 1F and J), where JNK acts as an anti-tumor
signaling. Signiﬁcantly, activation of Ras signaling in hpo /þEiger
clones canceled JNK's activity to inhibit tissue overgrowth caused by
hpo mutation; instead, it strongly enhanced F-actin accumulation
and tumorous overgrowth (Fig. 5J, compare to Fig. 1F and J). Toge-
ther, these data establish that hyperactive Ras signaling switches
JNK's activity from anti- to pro-tumor signaling by regulating the
Hippo pathway activity through F-actin accumulation.Discussion
JNK signaling has long been recognized as a dual-functional
signaling in regulating cancer development. Our present study in
Drosophila has unraveled the long-standing mystery of how JNK
signaling exerts both anti- and pro-tumor activities in different
cellular contexts. Our data show that JNK signaling suppresses
tissue growth by inhibiting Yki activity through elevation of Wts
activity, while it promotes tissue growth by activating Yki through
accumulation of F-actin in the presence of hyperactive Ras sig-
naling. Thus, hyperactive Ras acts as a signaling switch that con-
verts JNK's role from anti- to pro-tumor signaling.
Our genetic data suggest that hyperactive Ras-mediated switch
of JNK signaling plays a crucial role in growth factor signaling. It
has been reported in mammalian systems that EGFR signaling not
only activates the Ras-Raf-ERK pathway but also stimulates the
JNK pathway through Raf, Ral, Rac, or Cdc42 (Huang et al., 2004;
Karnoub and Weinberg, 2008; Linardou et al., 2009). Similarly, in
Drosophila imaginal disc, overexpression of EGFRCA activates both
Ras signaling (Biteau and Jasper, 2011) and JNK signaling (Fig. 5),
which cooperate to inactivate the Hippo pathway through F-actin
accumulation (Fig. 5). This machinery could be involved in the
normal developmental processes that utilize EGFR signaling and in
the development of human cancers such as non-small cell lung
cancer, where EGFR signaling plays a critical role. Indeed, in a lung
cancer cell line, EGF triggers JNK activation that promotes cell
proliferation (Bost et al., 1997). In addition, it has been shown in a
brain tumor cell line that EGF-dependent cell proliferation and
survival are suppressed by inhibition of JNK signaling (Antonyak
et al., 2002). Similarly to EGF, it has been reported that nerve
growth factor (NGF) signaling activates both the Ras-ERK pathway
and the JNK pathway to regulate neuronal cell survival and neural
maturation during development (Sofroniew et al., 2001; Xia et al.,
1995). Furthermore, ﬁbroblast growth factor (FGF), as well as
platelet-derived growth factor (PDGF), can activate both Ras-ERK
signaling and JNK signaling in ﬁbroblast cells (Borkham-Kam-
phorst et al., 2007; Tokuda et al., 2003; Tokuda et al., 2000). Thus,
it would be interesting to investigate whether Yki activation by
cooperation between hyperactive Ras and JNK signaling plays
important roles in such growth factor signaling during normal
development and homeostasis.
Our data reveal that hyperactive Ras and JNK signaling coop-
erate to induce F-actin accumulation through dJub, Rac1, and Dia,
thereby inactivating the Hippo pathway (Fig. 5). Although the
mechanism by which dJub contributes to accumulation of F-actin
and thereby leads to inactivation of the Hippo pathway is currently
unknown, data from recent studies provide some possible mole-
cular links. It has been shown in mammalian systems that Ajuba
can directly bind to Rac1 at the adherens junction and this inter-
action is crucial for Rac1 activation and F-actin accumulation(Marie et al., 2003; Nola et al., 2011). In addition, Rac1 activation
by Ajuba is facilitated by p21-activated kinase (PAK1)-dependent
phosphorylation of Ajuba (Nola et al., 2011). Thus, dJub may also
directly contribute to F-actin accumulation through interaction
with Rac1 at the adherens junction. On the other hand, it has been
shown that dJub can interact with α-catenin, which binds to
F-actin at the adherens junction in mammalian cells (Drees et al.,
2005), thereby leading to inactivation of the Hippo pathway when
cytoskeletal tension is increased in the cell (Rauskolb et al., 2014).
Interestingly, both JNK and ERK can directly phosphorylate dJub to
promote interaction between dJub and Wts (Reddy and Irvine,
2013; Sun and Irvine, 2013). Particularly, JNK phosphorylates dJub
at several sites of the N-terminal region (Sun and Irvine, 2013)
similarly to the PAK1-dependent phosphorylation of Ajuba in
mammals. In addition, it has been shown that JNK signaling is
essential for F-actin accumulation and Yki activation when Src64B
was overexpressed at the posterior compartment of the wing disc
(Fernandez et al., 2014). Furthermore, our data show that Ras-ERK
signaling is crucial for switching JNK signaling from anti-tumor to
pro-tumor activity. These observations suggest that activation of
JNK and Ras signaling lead to phosphorylation of dJub, which
regulates its interaction with α-catenin and Wts, as well as Rac1-
dependent F-actin accumulation, thereby causing inactivation of
the Hippo pathway (Fig. 5K). Although it has previously been
proposed that apical F-actin accumulation inactivates the Hippo
pathway (Fernández et al., 2011; Fernandez et al., 2014), the
mechanism by which F-actin accumulation negatively controls
Wts activity is still unknown. Importantly, many components of
the Hippo pathway, including Crumbs, Fat, Ex, Merlin (Mer), Hpo,
and Sav, have been shown to localize at the apical junction where
these molecules could ﬁnally activate Wts (Enderle and McNeill,
2013). In addition, it has been shown that Mer anchors Wts to
plasma membrane through its direct interaction regulated by actin
cytoskeleton (Yin et al., 2013). Interestingly, it has been reported
that the actin-associated LIM protein Zyxin (Zyx) inactivates the
Hippo pathway by destabilizing Wts through the interaction with
the atypical myosin Dachs (Rauskolb et al., 2011). Indeed, we
observed that depletion of zyx gene partially suppressed tissue
overgrowth, but not F-actin accumulation, that is induced by
activation of JNK and Ras signaling (data not shown), suggesting
the possibility that aberrant accumulation of F-actin affects Zyx
activity, which causes degradation of Wts at the apical junction.
While hyperactive Ras signaling is required for Yki activation in
clones of JNK-activated cells, a previous work has shown that JNK
signaling alone is sufﬁcient to activate Yki in the entire wing
pouch region using the rn-Gal4 driver (Sun and Irvine, 2011).
Intriguingly, it has been reported that the tissue entirely (or lar-
gely) expressing Crumbs (Chen et al., 2010), constitutively-active
form of aPKC (Sun and Irvine, 2011), DiaCA (Sansores-Garcia et al.,
2011), dominant-negative form of Rab5 (Robinson and Moberg,
2011), and RNAi of discs large (dlg) or scrib (Bunker et al., 2015;
Doggett et al., 2011) results in tissue overgrowth through Yki
activation, but these mutant cells do not overproliferate (but are
eliminated from the tissue) when they are induced as clones
(Doggett et al., 2011; Enomoto and Igaki, 2013; Takino et al., 2014,
and data not shown). Indeed, although JNK is activated in
DiaCA-expressing clones or Crb-expressing clones, Yki activity was
not clearly elevated in these clones (data not shown). Thus,
growth-related mutant cells activating JNK signaling behave in a
different way depending on whether they are induced in the entire
tissue (or large compartment of the imaginal disc) or they are
induced as clones surrounded by wild-type tissue. The mechanism
by which JNK-activating cells give different outcomes depending
on the situation they induced should be elucidated in the future
studies. Our data show in the clonal situation that JNK exerts its
anti-tumor activity through suppression of Yki activity without
M. Enomoto et al. / Developmental Biology 403 (2015) 162–171170increasing cell death (Fig. 3A–D, Fig. S3E and F, data not shown). It
remains to be elucidated how JNK signaling appropriately uses
two ways, growth suppression and cell death induction, in dif-
ferent cellular contexts.
Elevated Ras signaling is frequently associated with many types
of human cancers such as pancreatic cancer, a highly aggressive
cancer that mostly bears (90%) Ras activation (Downward,
2003). It has recently been shown in Ras-dependent cancers
including pancreatic cancers that YAP1, a mammalian ortholog of
Yki, can functionally substitute for oncogenic Ras when Ras sig-
naling is therapeutically blocked (Kapoor et al., 2014; Shao et al.,
2014), suggesting a crucial role of the Hippo pathway in tumor
relapse in Ras-dependent cancers. Thus, in such cases, therapeutic
compounds that activate JNK signaling might act as an anti-cancer
drug against tumors that lack Ras signaling. On the other hand,
compounds that inhibit JNK signaling might act as an anti-cancer
drug against cancers with elevated Ras and JNK signaling, which
can be induced by activating mutations in the EGFR gene observed
in many types of cancers (Arteaga and Engelman, 2014; Ciardiello
and Tortora, 2008). Thus, our study in Drosophila suggests that
assessment of activities of Ras and JNK signaling in individual
cancers could provide an ideal therapeutic strategy against neo-
plastic development.Acknowledgments
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